TUNE IN LIVE on Thursday at 9:30 a.m. ET for an extended discussion on longevity with Dr. Jordan Shlain, founder of Private Medical. Refresh your page if the player above does not display a livestream at that time. Wealthy investors and family offices are pouring billions into longevity startups, seeking both personal and financial rewards. From Jeff Bezos’s investment in Altos Labs to Sam Altman’s bet on Retro Biosciences and Peter Thiel’s funding of several longevity startups, the business of extending life has become a popular theme among the ultra-wealthy. Global investment in longevity biotech reached a record $18.4 billion in 2025, up from $4.7 billion in 2024, according to market research firm Longevity.Technology. Investments in the first half of 2026 already top $12 billion. “This isn’t hype chasing capital, it is capital following the science,” said Phil Newman, founder and CEO of Longevity.Technology. Along with biotech firms researching cell aging and regeneration, the burgeoning business of longevity also includes the surge in demand for peptides, testosterone and supplements, along with IV drips, red-light therapies and biomarker trackers. Instead of “lifespan,” the new marketing buzzwords in longevity are “healthspan” and “optimization,” promising more vitality and performance rather than anti-aging. The boom is being fueled in part by the younger generations of the wealthy, who want to improve their appearance and fitness levels. Longevity has also become a focus of wealth planning. A Bank of America survey of wealthy investors found that 94% are “taking steps to optimize their health” and 92% believe “longevity is important in wealth planning.”
